Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1900-1912
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1900
Table 2 Immune-related adverse events incidence by groups1, n (%)
IrAE by organ system n = 167
Grade < 2
Grade ≥ 2
Dermatological 43 (26)15 (9)
Colitis19 (11)10 (6)
Hepatitis 40 (24)29 (17)
Endocrine18 (11)11 (7)
Polyarthritis3 (1)1 (0)
Pneumonitis10 (6)9 (5)
Constitutional 52 (31)15 (9)
Other15 (9)22 (13)
1The incidence of immune-related adverse events (IrAEs) has been presented by patient groups categorized as those with IrAEs of grade < 2 and those with IrAEs of grade ≥ 2, stratified by the affected organ systems. IrAE: Immune-related adverse events.
  • Citation: Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D’Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(11): 1900-1912
  • URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1900.htm
  • DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1900